论文信息 - O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01) - 字舞流文

O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)

Y. Bang | N. Sugimoto | D. Sakai | Jeeyun Lee | H. Chung | M. Ryu | S. Iwasa | K. Shitara | K. Yamaguchi | H. Kawakami | M. Sugihara | H. Yabusaki | Kaku Saito | J. H. Lee | H. Chung | Y. Kawaguchi | T. Kamio | A. Kojima